Cutler Group LP Humanigen, Inc Call Options Transaction History

Cutler Group LP

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2022 Oct 25, 2022	SELL	$0.15 - $3.02 $1,455 - $29,294	-9,700 Reduced 98.98%	100 $0
Q2 2022 Aug 04, 2022	SELL	$1.76 - $3.33 $146,784 - $277,722	-83,400 Reduced 89.48%	9,800 $5,000
Q1 2022 Apr 14, 2022	BUY	$1.81 - $3.97 $161,995 - $355,315	89,500 Added 2418.92%	93,200 $29,000
Q4 2021 Jan 18, 2022	SELL	$3.66 - $8.22 $43,188 - $96,996	-11,800 Reduced 76.13%	3,700 $3,000
Q3 2021 Oct 26, 2021	BUY	$5.93 - $17.83 $43,882 - $131,942	7,400 Added 91.36%	15,500 $1,000
Q2 2021 Jul 19, 2021	BUY	$13.54 - $22.74 $23,018 - $38,658	1,700 Added 26.56%	8,100 $11,000
Q1 2021 Apr 26, 2021	SELL	$12.91 - $23.83 $83,915 - $154,895	-6,500 Reduced 50.39%	6,400 $9,000
Q4 2020 Jan 21, 2021	BUY	$7.97 - $21.66 $102,813 - $279,414	12,900 New	12,900 $36,000

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.